Dr. Karmali on Novel Agents in Relapsed/Refractory MCL

Video

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Despite best efforts, MCL remains an incurable disease, says Karmali. However, several advances have resulted in improvements in survival. Most notably, the BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) which have shown significant activity in the relapsed/refractory setting. Investigators anticipated that these agents would result in high response rates since BTK is an important protein of B-cell receptor signaling, which is a critical component of MCL differentiation, proliferation, and survival, explains Karmali. To date, both agents have shown response rates as high as 70% to 80%.

Given the impressive activity of these agents in such a heavily pretreated patient population, researchers are hoping to move these agents into earlier lines of therapy. However, whether their efficacy will translate to the frontline setting remains unclear, says Karmali.

Related Videos
A panel of 6 experts on follicular lymphoma and mantle cell lymphoma seated at a long desk
Eleonora Dondossola, PhD
William B. Pearse, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Harriet Kluger, MD, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; director, Yale SPORE in Skin Cancer; vice chair, Translational Research, Internal Medicine; chief, Division of Skin and Kidney Cancer; associate cancer center director, Education, Training and Faculty Development; deputy section chief, Medical Oncology, Yale Cancer Center
Robert DeBernardo, MD, section head, Obstetrics and Gynecology, Women’s Health Institute, Cleveland Clinic
Jacob Shreve, MD, MS, hematology/oncology fellow, Mayo Clinic
Abhishek Tripathi, MD, genitourinary medical oncologist, City of Hope